▎ 摘　　要

NOVELTY - Preparing sericin/graphene oxide composite hydrogel comprises e.g. taking silk fibroin-deficient silkworm cocoons, cut them, washing with deionized water, removing the water, and placing in sodium carbonate solution, stirring, centrifuging to remove the insoluble precipitate from above solution, collecting the supernatant to obtain clear sericin solution, and freeze-drying to obtain sericin powder, then completely dissolving sericin powder in phosphate buffer solution, stirring, adding methacrylic anhydride, reacting and performing dialysis of solution, and freeze-drying to obtain methacrylic anhydride-modified sericin, then dissolving methacrylic anhydride-modified sericin in deionized water to obtain methacrylic anhydride modified sericin solution; dissolving graphene oxide in deionized water to obtain graphene oxide dispersion, ultrasonicating and dispersing with water, mixing ultrasonically dispersed graphene oxide dispersion with methacrylic acid modified sericin solution. USE - The sericin/graphene oxide composite hydrogel is useful in preparing human tissue repair material, bone injury repair material and sericin/graphene oxide composite hydrogel freeze-dried stent (all claimed); and in medicine and cell loading, and tissue engineering repair. ADVANTAGE - The sericin/graphene oxide composite hydrogel has excellent biocompatibility and biodegradability, high mechanical strength and osteogenic induction properties. DETAILED DESCRIPTION - Preparing sericin/graphene oxide composite hydrogel, comprises (i) taking 1-5 g silk fibroin-deficient silkworm cocoons, cut them, washing them with deionized water, removing the water, and placing in 20-1000 ml of 0.01-0.02 mol/l sodium carbonate solution, stirring the reaction at 80-100 degrees C for 0.5-1 hour to completely dissolving the sericin, centrifuging to remove the insoluble precipitate from the above solution, collecting the supernatant for 2-3 days to obtain clear sericin solution, and freeze-drying to obtain sericin powder, (ii) completely dissolving sericin powder obtained in the step (i) in 10-100 ml 0.02-1 g/ml phosphate buffer solution having a pH of 7-10 and stirring to completely dissolve, adding 0.146-2.344 g methacrylic anhydride (based on per gram of sericin powder), stirring and reacting at normal temperature for 12-72 hours, and performing dialysis of solution after the reaction for 24-72 hours, and freeze-drying to obtain methacrylic anhydride-modified sericin, (ii) dissolving methacrylic anhydride-modified sericin obtained in the step (ii) in deionized water to obtain 10-20 g/100 ml methacrylic anhydride modified sericin solution; dissolving graphene oxide in deionized water to obtain 2.0-8.0 mg/ml graphene oxide dispersion, and ultrasonically processing for 10-30 minutes, and dispersing with water; and then mixing ultrasonically dispersed graphene oxide dispersion with methacrylic acid modified sericin solution in a mass ratio of 1:1500-1:75 to obtain mixed solution, (iv) dissolving 1-10 g Irgacure 2959 (RTM: Highly efficient non-yellowing radical photoinitiator) powder in 10-1000 ml deionized water, and heating the metal bath at 60-80 degrees C for 10-30 minutes to obtain Irgacure 2959 (RTM: Highly efficient non-yellowing radical photoinitiator) solution having a concentration of 0.1-10 g/100 ml, and (v) mixing sericin graphene oxide mixed solution obtained in (iii) with Irgacure 2959 (RTM: Highly efficient non-yellowing radical photoinitiator) solution described in (iv) in a volume ratio of 1:0.01-0.1, and irradiating by ultraviolet light to obtain sericin/graphene oxide composite hydrogel. INDEPENDENT CLAIMS are also included for: (1) sericin/graphene oxide composite hydrogel is obtained by above method; and (2) preparing sericin/graphene oxide composite hydrogel freeze-dried stent, comprising freezing sericin/graphene oxide composite hydrogel in a refrigerator at -80 degrees C for 24 hours, and placing frozen product in a vacuum freeze dryer and freez-drying to obtain final product.